Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study

• Published in: Journal of Nippon Medical School Vol. 82; no. 2; pp. 84 - 91
• Main Authors: Shima, Ayaka, Miyamoto, Masaaki, Kubota, Yoshiaki, Takagi, Gen, Shimizu, Wataru
• Format: Journal Article
• Language: English
• Published: Japan The Medical Association of Nippon Medical School 2015
• Subjects: Aged; Arteriosclerosis Obliterans - diagnosis; Arteriosclerosis Obliterans - drug therapy; Arteriosclerosis Obliterans - physiopathology; beraprost sodium; Biomarkers - blood; Creatinine - blood; cystatin C; Cystatin C - blood; Diabetic Nephropathies - diagnosis; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - physiopathology; diabetic nephropathy; Disease Progression; Epoprostenol - analogs & derivatives; Epoprostenol - therapeutic use; Female; Glomerular Filtration Rate - drug effects; Humans; Japan; Kidney Failure, Chronic - physiopathology; Kidney Failure, Chronic - prevention & control; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System - drug effects; renin-angiotensin system inhibitor; Time Factors; Treatment Outcome; Japan

Background: Inhibition of the renin-angiotensin system (RAS) has been used to treat diabetic nephropathy. However, RAS inhibition increases the risk of renal complications. In this study, we evaluated the effect of combining RAS inhibitor treatment with beraprost sodium (BPS), a prostaglandin I2 ana...